The January 2010 issue of the Journal of Commercial Biotechnology is now available. The links below will take you to the abstract for each paper:
Volume 16, Issue 1
Editorial
| Time for a new business model? | |
| Yali Friedman |
Commentary
| Why data exclusivity is the new patent protection | |
| Peter J Pitts |
| Follow-on biologic drug competition – No need for new marketing exclusivities | |
| Michael S Wroblewski, Elizabeth A Jex |
Articles
| Pharmaceutical royalties in licensing deals: No place for the 25 per cent rule of thumb | |
| Nigel Borshell, Adrian Dawkes |
| Exploring technology agglomeration patterns for multinational pharmaceutical and biotechnology firms | |
| Mark J Ahn, Michael Meeks, Sally Davenport, Rebecca Bednarek |
| Intellectual property landscape and patenting opportunity in biofuels | |
| Ramasamy Mannan |
| Challenges and opportunities in the licensing of renewable technologies | |
| Meredith Lloyd-Evans, Mike Gilbert, Ilian P Iliev |
| Ethiopia: Biotechnology for development | |
| Desta Berhe Sbhatu |
| Innovation and commercialisation in the stem cell industries in Australia: State strategies and other opportunities to build a competitive position in the global stem cell economy | |
| Olivia Harvey |
Legal and Regulatory Updates
| Using IP audits to optimize IP assets | |
| James G Cullem |
Book Reviews
| Book Review: Health-care investing: Profiting from the new world of pharma, biotech and health-care services | |
| Frank LaSaracina |
| Book Review: Aging, Biotechnology, and the Future | |
| Harley King |
![[Facebook]](http://www.biotechblog.com/wp-content/plugins/bookmarkify/facebook.png)
![[Google]](http://www.biotechblog.com/wp-content/plugins/bookmarkify/google.png)
![[LinkedIn]](http://www.biotechblog.com/wp-content/plugins/bookmarkify/linkedin.png)
![[Twitter]](http://www.biotechblog.com/wp-content/plugins/bookmarkify/twitter.png)
![[Email]](http://www.biotechblog.com/wp-content/plugins/bookmarkify/email.png)
{ 1 trackback }